Abstract：Objective To investigate the clinical application of Recombinant Human Prourokinase (rhPro-UK) combined with Tirofiban in percutaneous coronary intervention (PCI) of patients with high thrombus burden and acute ST-segment elevation myocardial infarction (ASTEMI). Methods A total of 93 patients with high thrombus burden ASTEMI who underwent PCI at the Sanya People′s Hospital from June 2017 to May 2018 were enrolled. The patients were divided into observation group (47 cases) and control group (46 cases) according to the random number table method. The patients in both groups were given conventional PCI treatment. The control group was slowly injected with Tirofiban at the distal end of the coronary artery by aspiration catheter, while the observation group was treated with rhPro-UK on the basis of the control group. Cardiac function indicators, blood flow related indicators, the incidence of major adverse cardiovascular events (MACE) and adverse reactions were compared between the two groups before and after 2 weeks of treatment. Results Compared with before treatment, the left ventricular ejection fraction in the two groups was significantly increased after treatment, while the left ventricular end-diastolic diameter and left ventricular end-systolic diameter were significantly lower, and the differences were statistically significant (P ＜ 0.05). The proportion of thrombolysis in myocardial infarction (TIMI) in blood flow grade 3 and myocardial perfusion grade 3 in the observation group after treatment were significantly higher than those in the control group, while the corrected TIMI blood flow frame count was significantly lower than the control group, and the differences were statistically significant (P ＜ 0.05). There were no significant differences in the incidence of MACE and adverse reactions between the observation group and the control group, and the differences were not statistically significant (P ＞ 0.05). Conclusion rhPro-UK combined with Tirofiban in ASTEMI patients with high thrombus burden who underwent PCI has better curative effect and higher safety of prognosis. It has a good effect on the heart function and blood flow of patients, and it is worthy of clinical promotion.
罗江宾 冯旭霞 陈其敬 王天松 何喜民. 重组人尿激酶原联合替罗非班在高血栓负荷ASTEMI患者PCI中的临床应用[J]. 中国医药导报, 2019, 16(26): 129-132,136.
LUO Jiangbin FENG Xuxia CHEN Qijing WANG Tiansong HE Ximin. Clinical application of Recombinant Human Prourokinase combined with Tirofiban in PCI of ASTEMI patients with high thrombus burden. 中国医药导报, 2019, 16(26): 129-132,136.
2019, Vol. 16 
京公网安备 11010502046598号